Luminescent PLGA Nanoparticles for Delivery of Darunavir to the Brain and Inhibition of Matrix Metalloproteinase-9, a Relevant Therapeutic Target of HIV-Associated Neurological Disorders

2021 ◽  
Author(s):  
Tiziana Latronico ◽  
Federica Rizzi ◽  
Annamaria Panniello ◽  
Valentino Laquintana ◽  
Ilaria Arduino ◽  
...  
Keyword(s):  
Matrix Metalloproteinase ◽  
Therapeutic Target ◽  
Neurological Disorders ◽  
Plga Nanoparticles ◽  
Matrix Metalloproteinase 9 ◽  
The Brain ◽  
Metalloproteinase 9

Increased matrix-metalloproteinase-2 and matrix-metalloproteinase-9 expression in the brain of dystrophic mdx mouse

Neuroscience ◽  
2006 ◽  
Vol 140 (3) ◽  
pp. 835-848 ◽  
Author(s):  
B. Nico ◽  
P. Corsi ◽  
R. Ria ◽  
E. Crivellato ◽  
A. Vacca ◽  
...  
Keyword(s):  
Matrix Metalloproteinase ◽  
Matrix Metalloproteinase 9 ◽  
Matrix Metalloproteinase 2 ◽  
Mdx Mouse ◽  
The Brain ◽  
Metalloproteinase 9

A Therapeutic Target of Cerebral Hemorrhagic Stroke: Matrix Metalloproteinase- 9

2017 ◽  
Vol 18 (12) ◽  
Author(s):  
Baoqi Dang ◽  
Xiaochun Duan ◽  
Zhong Wang ◽  
Weichun He ◽  
Gang Chen
Keyword(s):  
Matrix Metalloproteinase ◽  
Therapeutic Target ◽  
Hemorrhagic Stroke ◽  
Matrix Metalloproteinase 9 ◽  
Metalloproteinase 9

Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis

2006 ◽  
Vol 12 (3) ◽  
pp. 294-301 ◽  
Author(s):  
E Fainardi ◽  
M Castellazzi ◽  
T Bellini ◽  
M C Manfrinato ◽  
E Baldi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Matrix Metalloproteinase ◽  
Disease Activity ◽  
Neurological Disorders ◽  
Serum Levels ◽  
Matrix Metalloproteinase 9 ◽  
Active Matrix ◽  
Magnetic Resonance Imaging Mri ◽  
Metalloproteinase 9

In this study, we employed a sensitive activity assay system to measure cerebrospinal fluid (CSF) and serum levels of active matrix metalloproteinase-9 (MMP-9) in 37 relapsing-remitting (RR), 15 secondary progressive (SP) and nine primary progressive (PP) multiple sclerosis (MS) patients, grouped according to clinical and magnetic resonance imaging (MRI) evidence of disease activity. We also studied, as neurological controls, 48 patients with other inflammatory neurological disorders (OIND) and 48 with non-inflammatory neurological disorders (NIND). To assess active MMP-9/TIMP-1 circuit, CSF and serum levels of MMP-9 tissue inhibitor TIMP-1 were quantified by ELISA in the same patient population. CSF mean levels of active MMP-9, CSF active MMP-9/TIMP-1 ratios and intrathecal active MMP-9 synthesis, as indicated by specific index, were more elevated in MS than in NIND ( P <0.05, <0.02 and <0.02, respectively), serum active MMP-9/TIMP-1 ratio was higher in MS ( P<0.01) and OIND ( P<0.02) than in NIND, and serum TIMP-1 concentrations were lower in MS than in NIND ( P<0.05). More importantly, serum active MMP-9 mean levels, serum active MMP-9/TIMP-1 ratio and intrathecal production of active MMP-9 were increased in MS patients with clinical ( P<0.001, <0.001 and <0.05, respectively) and MRI ( P<0.001, <0.001 and <0.02, respectively) disease activity, whereas CSF mean concentrations of active MMP-9 and CSF active MMP-9/TIMP-1 ratio were enhanced only in MS patients with MRI evidence of disease activity ( P<0.02 and <0.01, respectively). Altogether, these findings suggest that a shift in MMP-9/TIMP-1 balance towards proteolytic activity of MMP-9 could be relevant in MS immune dysregulation. In addition, our results indicate that CSF and serum levels of active MMP-9 may represent a potential surrogate biomarker for monitoring MS disease activity. In particular, serum active MMP-9/TIMP-1 ratio seems to be a very appropriate indicator of ongoing MS inflammation, since it is easily measurable.

scholarly journals RhoA G17E/Vav1 signaling induces cancer invasion via matrix metalloproteinase-9 in gastric cancer

2021 ◽  
Author(s):  
Satoshi Nakamura ◽  
Masato Kitazawa ◽  
Yusuke Miyagawa ◽  
Makoto Koyama ◽  
Satoru Miyazaki ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Matrix Metalloproteinase ◽  
Cancer Cell ◽  
Therapeutic Target ◽  
Cancer Invasion ◽  
Small Gtpases ◽  
Matrix Metalloproteinase 9 ◽  
Diffuse Gastric Cancer ◽  
Rho Family ◽  
Metalloproteinase 9

Abstract Background: Ras homolog family member A (RhoA), a member of the Rho family of small GTPases, and Vav1, a guanine nucleotide exchange factor for Rho family GTPases, have been reported to activate pathways related to the actin cytoskeleton and regulation of cell shape, attachment, and motility. The interaction between these molecules in lymphoma is involved in malignant signaling, but its function in epithelial malignancy is unknown. Here, we investigated the malignant signal of mutant RhoA in gastric cancer and demonstrated the potential of RhoA G17E/Vav1 as a therapeutic target for diffuse gastric cancer. Methods: The RhoA mutants R5W, G17E, and Y42C were retrovirally transduced into the gastric cancer cell line MKN74. The stably transduced cells were used for morphology, proliferation, and migration/invasion assays in vitro. MKN74 cells stably transduced with ectopic wild-type RhoA and mutant RhoA (G17E) were used in a peritoneal xenograft assay. Results: The RhoA mutations G17E and Y42C induced morphological changes in MKN74. G17E induced Vav1 expression at the mRNA and protein levels and promoted the migration and invasion of MKN74. An RNA interference assay of Vav1 revealed that RhoA G17E enhanced cancer cell invasion via Vav1. Furthermore, immunoprecipitation revealed that Vav1 and RhoA G17E specifically bind and function together through matrix metalloproteinase-9. In a peritoneal xenograft model of nude mice, RhoA G17E promoted peritoneal dissemination, whereas Vav1 knockdown suppressed it. Conclusion: Overall, our findings indicate that RhoA G17E associated with Vav1 and promoted cancer invasion via matrix metalloproteinase-9 in gastric cancer cells. Thus, RhoA G17E/Vav1 signaling in diffuse gastric cancer may be a useful therapeutic target.

Matrix metalloproteinase-9 as a therapeutic target for the progression of fulminant liver failure with hepatic encephalopathy: A pilot study in mice

2013 ◽  
Vol 44 (6) ◽  
pp. 651-662 ◽  
Author(s):  
Tomohide Hori ◽  
Shinji Uemoto ◽  
Lindsay B. Walden ◽  
Feng Chen ◽  
Ann-Marie T. Baine ◽  
...  
Keyword(s):  
Hepatic Encephalopathy ◽  
Pilot Study ◽  
Matrix Metalloproteinase ◽  
Liver Failure ◽  
Therapeutic Target ◽  
Matrix Metalloproteinase 9 ◽  
Fulminant Liver Failure ◽  
Metalloproteinase 9
Sign in / Sign up

Export Citation Format

Share Document